MorphoSys Extends Alliance With Schering-Plough
Schering-Plough to have continued access to HuCAL GOLD
Schering-Plough has triggered its pre-existing option to extend the current collaboration with MorphoSys for another year.
Schering-Plough will have continued access to MorphoSys's proprietary antibody HuCAL GOLD, and contains options for therapeutic licenses.
For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to get license fees and milestone payments relating to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement.
Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform.
Simon Moroney, CEO of MorphoSys, said: We are pleased with Schering-Plough's decision to extend the current collaboration.
Related Insight
Suppliers Directory
Hapa - Late Stage Customisation and On Demand Printing Technologies
Hapa is the world leader in late stage customisation and on demand printing technologies for the pharmaceutical sector, delivering fast, accurate and value-creating packaging solutions.
Suppliers
Tecnosoft - Monitoring Systems for Temperature, Humidity and Pressure
Tecnosoft is a system development company working for big third party companies while also steering its own product line with its own brand. We have a lot of experience and a great know-how in the medical and geotechnical industry, having developed and produced data acquisition systems for both markets, in Italy and all around the world, for different leading companies.
Suppliers
PFC Pharma Focus - Planning And Conducting Clinical Phase I To IV Studies
The core competency of PFC Pharma Focus AG is the planning and conduction of clinical Phase I to IV studies. It is our aim to handle each project for which we are made responsible with great respect and care: for the patient, for the investigator, for the sponsor and for our collaborators.
Suppliers
Cryo Store – Biobanking, Packaging and Logistics of Temperature Sensitive Products
Cryo Store bv is based in the Netherlands and specialises in biobanking, packaging and logistics of temperature sensitive products and samples of various nature.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
GPC Streamliner - Autumn Edition
Published by Polymer Standards Service
White Papers
Staying Compliant with the Physician Payments Sunshine Act
Published by Alliance Life Sciences Consulting Group, Inc.
White Papers
Discovery Metrics – Creating the Right Balance
Published by Kinapse
White Papers
Fast and efficient quality controlof high performance membranes
Published by Phenom World
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.